A contact lens loaded with amniotic membrane and its preparation method and application

Abstract

The present invention provides an amniotic membrane-loaded contact lens, its preparation method, and its application. This invention innovates the bonding method between amniotic membrane and contact lens, replacing the previous method of simply bonding the amniotic membrane and contact lens with medical biological glue. This simplifies the bonding process between amniotic membrane and contact lens, making it suitable for industrial application. It also addresses the issues of traditional sutured amniotic membranes, which suffer from decreased mechanical support, rupture, and uneven coverage over time as they cover the ocular surface. The optimization and selection of materials not only meet the basic requirements of a non-toxic and harmless adhesive, but also take into account biocompatibility and the cornea's requirements for contact lens oxygen permeability. The use of amniotic membranes is more comfortable, eliminating the need for complex surgical procedures and the irritation associated with sutures. The design of using a contact lens as an amniotic membrane support allows amniotic lenses to provide superior support and protection for the covered ocular surface.

Description

Technical Field

[0001] The present invention generally relates to the field of biomedical materials, and in particular to an amniotic membrane-loaded contact lens and a preparation method and application thereof. Background Art

[0002] Corneal epithelial defects are a common clinical problem in ophthalmology, often caused by a variety of non-infectious causes, such as mechanical trauma, chemical burns, dry eye, neurotrophic keratitis, and autoimmune diseases. If corneal epithelial defects are not effectively repaired over a long period of time, they can lead to a series of serious complications, including corneal ulcers and corneal perforations, which can not only severely affect vision but may even cause blindness.

[0003] The amniotic membrane, the inner layer of the placenta, possesses unique biological properties and is widely used in ophthalmology. Its key advantages include: anti-inflammatory properties: The amniotic membrane contains various anti-inflammatory factors that can reduce inflammatory responses and aid in the treatment of ocular surface diseases; anti-scarring: The matrix components in the amniotic membrane can inhibit fibroblast activity, preventing scar formation; healing: The amniotic membrane is rich in growth factors that promote cell proliferation and migration, accelerating wound healing; and antibacterial properties: The amniotic membrane has certain antibacterial activity, which can reduce the risk of infection.

[0004] Due to these advantages, amniotic membrane is used in a variety of ophthalmic surgeries and treatments. Traditional amniotic membrane transplantation involves fixing the amniotic membrane to the corneal surface through suturing under topical anesthesia or peribulbar block anesthesia. However, the suturing fixation method has disadvantages such as complex operation, long operation time, and irritation from foreign bodies in the sutures. The suturing process may also increase the risk of infection and may cause additional mechanical damage to the patient's cornea. In addition, if the amniotic membrane at the suture site is damaged, it will rupture and dissolve prematurely, and a second operation may be required, increasing the patient's pain and financial burden. Summary of the Invention

[0005] The present invention prepares wearable amniotic membrane contact lenses by reorganizing the amniotic membrane into a pre-polymerized liquid and combining it with specially treated contact lenses. This can solve the problems of inconvenient application and poor comfort of existing amniotic membrane applications, while enhancing the therapeutic effect and improving the patient's wearing experience, providing an effective solution for clinical ophthalmic treatment.

[0006] In a first aspect of the present invention, a method for preparing an amniotic membrane-loaded contact lens is provided, comprising:

[0007] S1. Preparation of amniotic membrane recombinant prepolymer solution: methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder were mixed to obtain a mixed solution;

[0008] S2. After sterilizing the mixed solution, obtaining the amniotic membrane reconstitution prepolymer solution;

[0009] S3. Preparation of a contact lens treatment solution: methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate were mixed to obtain a contact lens treatment solution;

[0010] S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens;

[0011] S5. The amniotic membrane reconstitution prepolymer solution obtained in step S2 is evenly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain an amniotic membrane-loaded contact lens.

[0012] Preferably, the pore diameter of the methacrylated gelatin after light curing is between 10 μm and 200 μm, and the porosity is 30-60%.

[0013] More preferably, the pore diameter of the methacrylated gelatin after light curing is between 100 μm and 200 μm, and the porosity is 50-60%.

[0014] Preferably, the contact lens is a soft hydrophilic contact lens with a water content of 34-40%.

[0015] Preferably, in step S1, the mass percentage concentrations of methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50%, respectively.

[0016] Preferably, in step S3, the mass percentage concentrations of methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate in the contact lens treating solution are 6-8% and 0.2-0.5%, respectively.

[0017] Preferably, in step S4, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

[0018] Preferably, in step S5, the conditions for illumination are: wavelength between 320 and 400 nanometers, and illumination for 30-120 seconds.

[0019] In a second aspect of the present invention, there is provided an amniotic membrane-loaded contact lens produced according to the above-mentioned method for producing an amniotic membrane-loaded contact lens.

[0020] In the third aspect of the present invention, a method for preparing the above-mentioned amniotic membrane-loaded contact lens and the use of the amniotic membrane-loaded contact lens in preparing medical devices for treating or alleviating corneal epithelial defects and promoting corneal epithelial cell repair are provided.

[0021] The wearable amniotic membrane-loaded contact lens of the present invention has the following beneficial effects:

[0022] 1. The bonding method of amniotic membrane and contact lens has been innovated, changing the previous method of simply bonding the amniotic membrane and contact lens with medical biological glue, simplifying the bonding procedure of amniotic membrane and contact lens, and making it suitable for industrial application.

[0023] 2. It solves the problem of traditional sutured amniotic membrane causing mechanical support to decrease as the time of covering the ocular surface increases, resulting in amniotic membrane rupture and uneven coverage.

[0024] 3. In terms of material optimization and selection, the present invention not only meets the basic requirement of non-toxic and harmless adhesives, but also takes into account the biocompatibility and corneal requirements for contact lens oxygen permeability.

[0025] 4. The use of amniotic membrane is more comfortable, does not require complicated surgical procedures, and does not cause irritation caused by sutures.

[0026] 5. The design of using contact lens as amniotic membrane support enables the amniotic membrane to provide better support and protection for the covered ocular surface. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a real photo of a wearable amniotic contact lens.

[0028] Figure 2 These are gross photographs of the rabbit cornea before and after wearing the amniotic membrane contact lens in Comparative Example 1.

[0029] Figure 3 This is the sodium fluorescein staining image of the cornea in Comparative Example 1.

[0030] Figure 4 is the healing rate of the cornea in Comparative Example 1.

[0031] Figure 5 This is a corneal slit lamp photo and sodium fluorescein staining image of the cornea of ​​the PEGDA group in Comparative Example 2.

[0032] Figure 6 This is a corneal slit lamp photo and sodium fluorescein staining image of the cornea of ​​the ordinary GelMA group in Comparative Example 2. DETAILED DESCRIPTION

[0033] To address the technical problems of existing amniotic membrane transplantation, which involves a single method, complex operation, low patient comfort, and limited protective performance, the present invention provides a wearable amniotic membrane-loaded contact lens, a preparation method, and applications thereof. The present invention achieves this objective through the following technical solutions.

[0034] The method for preparing a wearable amniotic membrane-loaded contact lens (amniotic membrane contact lens) comprises:

[0035] S1. Preparation of amniotic membrane reconstitution prepolymer solution: Mix methacrylated gelatin (GelMA hydrogel), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder to obtain a mixed solution;

[0036] Preferably, the mass percentage concentrations of GelMA hydrogel, lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50%, respectively; more preferably, the mass percentage concentrations are 6-8%, 0.2-0.5% and 20-30%, respectively.

[0037] Preferably, the pore diameter of the GelMA hydrogel after photocuring is between 10 μm and 200 μm, and the porosity is 30-60%.

[0038] More preferably, the pore diameter of the GelMA hydrogel after photocuring is between 100 μm and 200 μm, and the porosity is 50-60%.

[0039] In the present invention, there is no limitation on the solvent used to dissolve the GelMA hydrogel, LAP and amniotic membrane powder, and the solvent may be water, distilled water or deionized water.

[0040] The present invention has no limitation on the uniform mixing method, and those skilled in the art can complete the mixing according to conventional operations.

[0041] S2. After sterilizing the mixed solution, obtaining the amniotic membrane reconstitution prepolymer solution;

[0042] The present invention has no limitation on the sterilization method, and those skilled in the art can perform the sterilization according to conventional operations. Preferably, pasteurization is used.

[0043] S3. Preparation of contact lens treatment solution: GelMA hydrogel and LAP were mixed to obtain a contact lens treatment solution;

[0044] Preferably, the mass percentage concentrations of GelMA hydrogel and LAP in the treatment solution are 6-8% and 0.2-0.5%, respectively.

[0045] In the present invention, there is no limitation on the solvent used to dissolve the GelMA hydrogel and LAP, and the solvent may be water, distilled water, deionized water, or PBS phosphate buffer.

[0046] The present invention has no limitation on the uniform mixing method, and those skilled in the art can complete the mixing according to conventional operations.

[0047] S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens;

[0048] The present invention has no limitation on the immersion method, and those skilled in the art can perform the immersion according to conventional operations. Optionally, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

[0049] S5. The amniotic membrane reconstitution prepolymer solution obtained in step S2 is evenly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain a wearable amniotic membrane contact lens.

[0050] The present invention does not limit the coating amount of the amniotic membrane reconstitution prepolymerization liquid. Those skilled in the art can apply different amounts of the amniotic membrane reconstitution prepolymerization liquid to the surface of the pretreated contact lens (for example, the inner surface optical zone, the entire inner surface area, or the entire inner and outer surfaces) according to actual needs.

[0051] Preferably, the amniotic membrane reconstitution prepolymer solution is applied to the inner surface of the pretreated contact lens.

[0052] The loading capacity of amniotic membrane can be adjusted by adjusting the concentration and coating amount of the amniotic membrane reconstitution prepolymer solution. For example, applying 90 μl of amniotic membrane reconstitution prepolymer solution containing 20%-30% amniotic membrane powder to the inner surface of a contact lens for curing and cross-linking will result in an amniotic membrane loading capacity of 23 mg per lens.

[0053] In the present invention, the optical zone on the inner surface of the contact lens refers to the central part of the optical zone on the back surface of the contact lens. The curvature radius of this part is designed to match the shape of the cornea to ensure that light passing through this area can be clearly focused on the retina.

[0054] Preferably, the contact lens is a soft hydrophilic contact lens with a water content of 34-40%. When the water content is greater than 40%, it is not conducive to the adhesion of the amniotic membrane reconstitution prepolymer solution.

[0055] Preferably, the illumination conditions are: wavelength between 320 and 400 nanometers, and illumination for 30-120 seconds.

[0056] In the present invention, the above method further includes a pre-treatment step of the amniotic membrane, including: taking fresh amniotic membrane, rinsing it with sterile saline, and then rinsing it in antibiotic saline; scraping off the spongy layer, part of the fibroblast layer and serous exudate under a microscope; attaching a sterile nitrocellulose membrane (NC membrane) thereon with the amniotic epithelial surface facing up; and trimming it to an appropriate size according to actual needs.

[0057] In the present invention, the above method further includes a step of preparing amniotic membrane powder, including: pre-freezing the sterilized amniotic membrane, for example, placing it in a -80° refrigerator and freezing it for 20 minutes; freeze-drying the pre-frozen amniotic membrane, for example, treating it in a vacuum freeze dryer at -53° for 48 hours; grinding the freeze-dried amniotic membrane into powder, for example, cutting the amniotic membrane into small pieces and transferring them to a centrifuge tube containing grinding beads, and grinding it into powder using a grinder at 30 times / second, 90 seconds, 3 times.

[0058] In the present invention, the above method further comprises a post-processing step, namely, washing the reacted amniotic membrane, pre-treated contact lens, and amniotic membrane contact lens by placing them in a buffer solution for washing to remove unreacted reagents and by-products.

[0059] In the present invention, there is no limitation on the buffer used for the washing reaction, and those skilled in the art can select, for example, PBS buffer according to actual conditions.

[0060] In the present invention, there is no limit to the number and time of cleaning, and those skilled in the art can determine it according to actual conditions, for example, cleaning 3-10 times, each time for 2-60 minutes.

[0061] The technical solution of the present invention is based on the following principle: GelMA (gelatin methacrylate) is a photosensitive biomaterial synthesized by reacting the amine group (-NH2) on the gelatin molecule with methacrylic anhydride (MA) to introduce a methacrylate group (-C(=O)OCH3). This modification gives gelatin the ability to undergo photocrosslinking, that is, under the irradiation of ultraviolet light, GelMA can quickly form a stable three-dimensional network structure. Porous GelMA hydrogel is a material with a special microstructure. Its porous structure can provide larger space and more efficient material exchange channels, which is beneficial to cell proliferation, growth, and the transmission of nutrients and metabolic waste.

[0062] The preparation of porous GelMA hydrogels typically involves mixing GelMA with another polymer to form a two-phase or multiphase system. For example, by mixing GelMA with polyvinyl alcohol (PEO), hydrogels with different porosities can be created. By adjusting the volume fraction of PEO and the mixing time, the pore size and porosity can be controlled. In the present invention, the GelMA hydrogel is a porous GelMA hydrogel with a pore size of 10um-200um and a porosity of 30-60%, so that the amniotic membrane contact lens has good oxygen permeability and can be worn for a long time without causing corneal hypoxia.

[0063] The present invention is further illustrated by the following examples which are intended to illustrate the present invention. The following examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. Unless otherwise indicated, the technical and scientific terms used herein are those generally understood by those skilled in the art to which the present invention belongs. In the examples, where specific conditions are not specified, conventional conditions or conditions recommended by the manufacturer were used. Reagents or instruments used where the manufacturer is not specified are conventional products that can be obtained commercially.

[0064] Sources

[0065] The amniotic membrane was donated by the obstetrics department of the Provincial Hospital.

[0066] High-porosity GelMA hydrogel was purchased from Suzhou Yongqinquan Intelligent Equipment Co., Ltd. The product model is EFL-GM-PR-001, with a porosity / pore size of 30-40% / 10-100 μm; EFL-GM-PR-002, with a porosity / pore size of 50-60% / 100-200 μm.

[0067] Invisible corneal contact lenses were purchased from Bausch + Lomb Co., Ltd. The product is a soft hydrophilic contact lens with a water content of 36% and a nominal oxygen permeability coefficient of 68.3×10 -11 (cm 2 / s)[mLO2 / (mL×hPa)], lens diameter: 14mm, base curve radius: 8.6mm, center thickness: 0.07mm.

[0068] Example 1

[0069] To prepare a wearable amniotic membrane contact lens, follow these steps:

[0070] S1. Prepare amniotic membrane reconstitution prepolymer solution: mix high-porosity GelMA hydrogel (porous GelMA), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) and amniotic membrane powder to obtain a mixed solution.

[0071] The mass percentage concentrations of high-porosity GelMA hydrogel (porous GelMA), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5%, and 20-50%, respectively, such as 7%, 0.3%, and 25%; 7.5%, 0.4%, and 30%; 6%, 0.2%, and 20%; and 8%, 0.5%, and 50%. The solvent is water.

[0072] To fully dissolve and mix the substance, the mixture can be placed in a 37° constant temperature water bath for 15 minutes, taken out and shaken for 30 seconds to fully mix, and the above steps can be repeated three times as needed.

[0073] S2. Pasteurize the mixed solution to obtain amniotic membrane reconstitution prepolymer solution.

[0074] Sterilization method: 80° constant temperature water bath, 30 minutes; 0°C ice water, 5 minutes; the above steps are repeated 3-5 times.

[0075] S3. Prepare contact lens treatment solution: mix high-porosity GelMA hydrogel (porous GelMA) and LAP evenly to obtain contact lens treatment solution.

[0076] The mass percentage concentrations of high-porosity GelMA hydrogel (porous GelMA) and LAP in the treatment solution are 6-8% and 0.2-0.5%, for example, 6% and 0.2%; 7% and 0.4%, respectively. The solvent is PBS phosphate buffer.

[0077] S4. Pre-treat the contact lens: immerse the contact lens in contact lens treatment solution at room temperature (15-25°C) for 30 minutes to obtain a pre-treated contact lens.

[0078] S5. The amniotic membrane reconstitution prepolymer solution obtained in step S2, for example, 80-100 μl, 20-30 μl, is evenly coated on the inner surface (the side facing or contacting the ocular surface) of the pretreated contact lens in step S4, and then irradiated under ultraviolet light for 30 seconds to cause in-situ curing and cross-linking to obtain a wearable amniotic membrane-loaded contact lens ( Figure 1 ).

[0079] To ensure that the amniotic membrane reconstitution prepolymer solution is evenly applied to the inner surface of the pretreated contact lens, the contact lens coated with the amniotic membrane reconstitution prepolymer solution is placed on an inner surface molding mold and then irradiated under a UV lamp to complete in-situ curing and crosslinking. After demolding, a wearable amniotic membrane contact lens is obtained.

[0080] Comparative Example 1

[0081] Twelve New Zealand white rabbits were anesthetized and the corneal epithelium and basement membrane were scraped off within 11 mm using an epithelial scraper. Six rabbits were randomly selected to wear the wearable amniotic membrane contact lenses prepared in Example 1 (amniotic lens group); the remaining six rabbits were not treated postoperatively (control group). One and two days after surgery, corneal slit lamp photography and sodium fluorescein staining were performed to record the healing of various corneal epithelial conditions, redness of the eyes, secretions, and other abnormalities. Figure 2 As shown in the figure, the experimental animals were shown before and after wearing the amniotic lens. The contact lens fit well and had good transparency. Figure 3 As shown, 24 hours after surgery, the experimental group showed more natural blinking behavior, very little sticky secretion, and milder inflammatory response because of the protection of wearable amniotic membrane contact lenses; the control group closed their eyes due to epithelial damage, had obvious inflammatory response, and severe conjunctival congestion.

[0082] One month after surgery, the corneal epithelial healing rates of the two groups were calculated using Image J software ( Figure 4 ), the results showed that the healing speed of corneal epithelium in the amniotic mirror group was significantly faster than that in the blank control group, and the difference was statistically significant.

[0083] Comparative Example 2

[0084] Grouping: Twelve New Zealand white rabbits were randomly divided into three groups, four rabbits in each group, namely porous GelMA group, PEGDA group, and ordinary GelMA group.

[0085] After the rabbits were anesthetized, the corneal epithelium and basement membrane within an area of ​​11 mm were scraped off with an epithelial knife.

[0086] The porous GelMA group was given the wearable amniotic membrane contact lens prepared in Example 1 after surgery.

[0087] In the PEGDA group, PEGDA-based amnioscopic surgery was performed.

[0088] The difference between the PEGDA-based amniotic membrane lens and the amniotic membrane contact lens prepared in Example 1 is that the PEGDA-based amniotic membrane lens is not loaded with a pre-treated corneal contact lens. Since the oxygen permeability of the PEGDA is poor after light curing, adding another layer of corneal contact lens will further reduce the oxygen permeability. At the same time, due to the inherent characteristics of the material after curing, 0.2% PEGDA exhibits poor ductility and high brittleness, which cannot be well adapted to the contact lens. The specific preparation steps are as follows:

[0089] Steps S1 and S2 are the same as those in Example 1.

[0090] S3. Take 20-30ul, for example 25ul, of the amniotic membrane PEGDA mixture and add it to the contact lens molding mold. Press the mold evenly to mold the amniotic membrane PEGDA mixture, and then irradiate under ultraviolet light to complete in-situ curing and crosslinking. After demolding, the PEGDA-based amniotic membrane contact lens is obtained.

[0091] The ordinary GelMA group was given an ordinary GelMA-based amnioscopic lens after surgery.

[0092] The preparation method of the ordinary GelMA-based amniotic membrane contact lens differs from that in Example 1 in that the pretreated corneal contact lens is not loaded thereon. The steps for preparing the ordinary GelMA-based amniotic membrane contact lens are as follows:

[0093] Steps S1 and S2 are the same as those in Example 1.

[0094] S3. Take 20-30ul, for example 25ul, of the amniotic membrane GelMA mixture and add it to the contact lens molding mold. Press the mold evenly to mold the amniotic membrane GelMA mixture, and then irradiate under UV light to complete in-situ curing and crosslinking. After demolding, the GelMA-based amniotic membrane contact lens is obtained.

[0095] Corneal slit lamp photography and fluorescein sodium staining were performed on the 1st, 3rd, and 5th day after surgery. Figure 5 、 Figure 6 ), record the healing of various corneal epithelial conditions and redness, secretions and other abnormal conditions.

[0096] The results show:

[0097] Porous GelMA group: No lens detachment occurred 36 hours after surgery. The porous GelMA group also demonstrated a milder inflammatory response, no conjunctival congestion, no ciliary congestion, faster healing, less secretion, and most importantly, no neovascularization.

[0098] In the PEGDA group, due to its greater fragility, lens breakage was the main cause of lens detachment during postoperative follow-up observations. The lens detachment rate reached 50% 12 hours after surgery, increased to 62% 24 hours after surgery, and reached 75% 36 hours after surgery. Among them, the proportion of lens detachment due to lens breakage reached 83%, that is, 5 out of 6 lenses detached were due to lens breakage due to the excessive fragility of PEGDA.

[0099] Compared with the PEGDA group, the ordinary GelMA group had better ductility of the lens and rarely fell off due to lens breakage. The main reason for the lens falling off was that the material underwent a certain degree of wrinkling after curing, resulting in a certain amount of warping around the lens, affecting the close fit between the lens and the ocular surface. At the same time, its better biocompatibility and amniotic membrane release rate caused its degradation rate to be faster than that of PEGDA-based amniotic membrane contact lenses, which also accelerated the lens falling off. In the observation 12 hours after surgery, the lens falling off rate reached 37%. In the observation 24 hours after surgery, the lens falling off rate increased to 50%. In the observation 36 hours after surgery, the lens falling off rate reached 62%, of which the proportion of falling off due to warping reached 40%, that is, 2 of the 5 fallen lenses fell off due to warping, and the remaining 3 fell off due to degradation as the observation time increased.

[0100] The PEGDA group and the ordinary GelMA group showed more severe inflammatory reactions, with severe conjunctival congestion and more secretions. The rabbits showed obvious photophobia and their eyes were tightly closed.

[0101] The above specific embodiments do not limit the scope of protection of the present invention. Those skilled in the art will appreciate that various modifications, combinations, sub-combinations, and substitutions may be made based on design requirements and other factors. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention are intended to be included within the scope of protection of the present invention.

Claims

1. A method for preparing an amniotic membrane-loaded contact lens, comprising: S1. Preparation of amniotic membrane recombinant prepolymer solution: methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder were mixed to obtain a mixed solution; S2. After sterilizing the mixed solution, obtaining the amniotic membrane reconstitution prepolymer solution; S3. Preparation of a contact lens treatment solution: methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate were mixed to obtain a contact lens treatment solution; S4. Pre-treating the contact lens: soaking the contact lens in a contact lens treatment solution to obtain a pre-treated contact lens; S5. The amniotic membrane reconstitution prepolymer solution obtained in step S2 is evenly coated on the surface of the pretreated contact lens in step S4; and light is irradiated to cause in-situ curing and cross-linking to obtain an amniotic membrane-loaded contact lens.

2. The method for preparing a contact lens according to claim 1, wherein: After photocuring, the pore diameter of methacrylated gelatin is between 10um and 200um, and the porosity is 30-60%.

3. The method for preparing a contact lens according to claim 2, wherein: After photocuring, the pore diameter of methacrylated gelatin is between 100um and 200um, and the porosity is 50-60%.

4. The method for preparing a contact lens according to claim 1, wherein: The contact lenses are soft hydrophilic contact lenses with a water content of 34-40%.

5. The method for preparing a contact lens according to claim 1, wherein: In step S1, the mass percentage concentrations of methacrylated gelatin, lithium phenyl-2,4,6-trimethylbenzoylphosphinate and amniotic membrane powder in the mixed solution are 6-8%, 0.2-0.5% and 20-50%, respectively.

6. The method for preparing a contact lens according to claim 1, wherein: In step S3, the mass percentage concentrations of methacrylated gelatin and lithium phenyl-2,4,6-trimethylbenzoylphosphinate in the contact lens treating solution are 6-8% and 0.2-0.5%, respectively.

7. The method for preparing a contact lens according to claim 1, wherein: In step S4, the contact lens is completely immersed in the contact lens treatment solution at 15-40° C. for 20-60 minutes.

8. The method for preparing a contact lens according to claim 1, wherein: In step S5, the conditions of light irradiation are: wavelength 320 to 400 nanometers, irradiation 30-120 seconds.

9. An amniotic membrane-loaded contact lens produced according to the method for producing an amniotic membrane-loaded contact lens according to any one of claims 1 to 8.

10. The method for preparing an amniotic membrane-loaded contact lens according to any one of claims 1 to 8 and use of the amniotic membrane-loaded contact lens according to claim 9 in preparing a medical device for treating or alleviating corneal epithelial defects and promoting corneal epithelial cell repair.

Images